VOLPARA HEALTH TECHNOLOGIES LIMITED Financials Volpara Health Technologies Limited
Equities
VHT
NZVHTE0001S6
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.14 AUD | 0.00% |
|
0.00% | +3.17% |
| Apr. 12 | Volpara Health Technologies Secures Approval for Lunit’s Proposed Takeover | MT |
| Apr. 12 | Transcript : Volpara Health Technologies Limited - Shareholder/Analyst Call |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 251.7 | 233.8 | 326.3 | 221.7 | 193.1 | 290 | - | - |
| Enterprise Value (EV) 1 | 238.2 | 208 | 301 | 207.4 | 183.2 | 283.1 | 277.7 | 262.2 |
| P/E ratio | -21.2 x | -11.5 x | -19.7 x | -13.8 x | -20.3 x | -51.7 x | -792 x | 36 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 46.7 x | 15.4 x | 17 x | 9.29 x | 5.9 x | 7 x | 5.9 x | 5.25 x |
| EV / Revenue | 44.2 x | 13.7 x | 15.7 x | 8.69 x | 5.6 x | 6.83 x | 5.65 x | 4.75 x |
| EV / EBITDA | -21.3 x | -10.7 x | -25.7 x | -16.1 x | -32.1 x | -335 x | 65.5 x | 21.3 x |
| EV / FCF | -22.9 x | -13.5 x | -22.7 x | -20 x | -50.5 x | 1,522 x | 103 x | 33.2 x |
| FCF Yield | -4.36% | -7.38% | -4.41% | -5.01% | -1.98% | 0.07% | 0.97% | 3.02% |
| Price to Book | 18.6 x | 4.79 x | 4.76 x | 4.19 x | 4.03 x | 6.89 x | 6.96 x | 5.86 x |
| Nbr of stocks (in thousands) | 179,800 | 218,480 | 251,019 | 251,935 | 254,090 | 254,374 | - | - |
| Reference price 2 | 1.400 | 1.070 | 1.300 | 0.8800 | 0.7600 | 1.140 | 1.140 | 1.140 |
| Announcement Date | 5/31/19 | 5/28/20 | 5/26/21 | 5/25/22 | 5/24/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.389 | 15.21 | 19.18 | 23.85 | 32.71 | 41.42 | 49.13 | 55.18 |
| EBITDA 1 | -11.16 | -19.36 | -11.71 | -12.86 | -5.704 | -0.844 | 4.236 | 12.34 |
| EBIT 1 | -11.45 | -21.45 | -18.28 | -14.78 | -10.45 | -6.113 | -1.037 | 7.064 |
| Operating Margin | -212.42% | -141.04% | -95.34% | -61.97% | -31.95% | -14.76% | -2.11% | 12.8% |
| Earnings before Tax (EBT) 1 | -11.07 | -20.8 | -17.84 | -14.76 | -10.63 | -5.798 | 0.948 | 11.4 |
| Net income 1 | -11.05 | -18.99 | -16.46 | -15.02 | -9.157 | -5.524 | -0.4415 | 7.978 |
| Net margin | -205.12% | -124.86% | -85.83% | -62.96% | -27.99% | -13.34% | -0.9% | 14.46% |
| EPS 2 | -0.0659 | -0.0934 | -0.0659 | -0.0640 | -0.0374 | -0.0221 | -0.001440 | 0.0317 |
| Free Cash Flow 1 | -10.39 | -15.35 | -13.27 | -10.38 | -3.627 | 0.186 | 2.698 | 7.909 |
| FCF margin | -192.78% | -100.96% | -69.19% | -43.51% | -11.09% | 0.45% | 5.49% | 14.33% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 63.69% | 64.11% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 99.14% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 5/31/19 | 5/28/20 | 5/26/21 | 5/25/22 | 5/24/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: März | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | 6.908 | 8.349 | 8.98 | 10.27 | 11.86 | 12.6 | 15.64 | 16.94 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -7.86 | -13.64 | -9.333 | -9.025 | -8.636 | -6.59 | -5.01 | -5.4 | -4.707 | -1.954 |
| Operating Margin | -113.78% | -163.42% | -103.93% | -87.89% | -72.78% | -52.31% | -32.03% | -31.88% | - | - |
| Earnings before Tax (EBT) | -7.551 | - | - | -8.856 | -8.625 | -6.574 | -5.14 | -5.449 | - | - |
| Net income | -7.532 | - | - | -8.117 | -8.194 | -7.245 | -4.897 | -4.219 | - | - |
| Net margin | -109.04% | - | - | -79.04% | -69.06% | -57.51% | -31.31% | -24.91% | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/19/19 | 5/28/20 | 11/24/20 | 5/26/21 | 11/22/21 | 5/25/22 | 11/22/22 | 5/24/23 | 11/20/23 | - |
1AUD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: März | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 13.5 | 25.8 | 25.3 | 14.3 | 9.93 | 6.91 | 12.3 | 27.8 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -10.4 | -15.4 | -13.3 | -10.4 | -3.63 | 0.19 | 2.7 | 7.91 |
| ROE (net income / shareholders' equity) | -126% | -61.2% | -28% | -25.2% | -18% | -12.9% | -0.55% | 17% |
| ROA (Net income/ Total Assets) | -89.3% | -44.3% | -20.9% | -18.7% | -12.2% | -14.2% | 1.8% | - |
| Assets 1 | 12.38 | 42.9 | 78.85 | 80.21 | 74.84 | 38.9 | -24.53 | - |
| Book Value Per Share 2 | 0.0800 | 0.2200 | 0.2700 | 0.2100 | 0.1900 | 0.1700 | 0.1600 | 0.1900 |
| Cash Flow per Share 2 | -0.0600 | -0.0700 | -0.0500 | -0.0400 | -0.0100 | -0.0100 | 0.0200 | 0.0600 |
| Capex 1 | 0.37 | 0.45 | 0.07 | 0 | 0.03 | 0.57 | 0.54 | 0.54 |
| Capex / Sales | 6.87% | 2.97% | 0.37% | 0.02% | 0.09% | 1.38% | 1.09% | 0.98% |
| Announcement Date | 5/31/19 | 5/28/20 | 5/26/21 | 5/25/22 | 5/24/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
3
Last Close Price
1.14
AUD
Average target price
0.9959
AUD
Spread / Average Target
-12.64%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +3.17% | 189M | |
| +4.36% | 32.47B | |
| +14.14% | 7.45B | |
| +22.93% | 3.89B | |
| -16.29% | 3.17B | |
| -25.96% | 1.28B | |
| -36.14% | 1.09B | |
| -35.42% | 902M | |
| -0.13% | 893M | |
| -24.12% | 857M |
- Stock Market
- Equities
- VHT Stock
- Financials Volpara Health Technologies Limited
